Equitable (EQH) Q1 2026 Earnings Transcript

Equitable Holdings reported Q1 2026 non-GAAP operating EPS of $1.68, up 25% year over year, with AUM rising 9% to $1.1 trillion and net income of $621 million. Management reaffirmed 2026 EPS growth above the high end of its 12%-15% target range and highlighted strong capital returns, including $223 million returned this quarter and an active buyback plan. The pending CoreBridge merger remains the main strategic catalyst, with at least $500 million of expense synergies, 10%+ run-rate EPS accretion by 2028, and a combined platform expected to exceed $4 billion of annual cash flow.

Analysis

EQH is now behaving more like a capital arbitrage than a pure operating story: the combo of a depressed multiple, resumption of repurchases, and a fixed exchange ratio creates a window where equity buybacks can be more accretive than most strategic actions. The key second-order effect is that management can shrink the share count before the merger closes without diluting the economics of the deal, which should mechanically lift per-share optics and support the stock into the proxy / vote milestones over the next 1-3 months.

The bigger beneficiary may be AB, not the insurance segment. The market is likely underestimating how much higher-quality sticky balance-sheet assets can do for fee stability and product shelf space, especially when CoreBridge liability origination gets routed through multiple asset managers. That said, the announced “incremental assets” framing may prove optimistic if those inflows are slow-moving or low-fee; the nearer-term P&L bridge is still mostly expense discipline and buybacks, not revenue synergy.

The main risk is that investors are anchoring on the merger as a cleaner capital-return story while the alternatives book is quietly losing momentum. If alternatives returns stay sub-guidance for several quarters, the market will start haircutting the ‘all-weather cash flow’ narrative and focus on the fact that a chunk of the uplift is market-sensitive and not fully controllable. In that scenario, the stock could still work, but the multiple expansion likely stalls until the company proves the new run-rate through Q2/Q3 and the proxy timeline clears.

Contrarian read: the sell-side may be overfocusing on headline accretion and underappreciating how much optionality sits in capital deployment. If the company executes even a moderate ASR at current valuations, the 2026 EPS guide becomes easier, not harder, and any later revenue synergy surprise becomes upside on top. This is a setup where patience through event risk may be more valuable than trying to chase the first post-announcement move.

Key Decisions for Investors

• Long EQH common into the proxy window and vote cycle (1-3 months): buybacks at a discounted valuation should be immediately accretive; use a 10-15% upside target and a tight stop if the stock breaks on merger-execution skepticism.
• Pair trade: long EQH / short RGA over the next 2-4 months: EQH has a clearer buyback and merger catalyst, while RGA is more exposed to mortality normalization and lacks comparable capital-return optionality.
• Consider EQH Jan-2027 call spreads: the merger is a 12-24 month story, and upside is most likely from multiple re-rating plus synergy realization; call spreads cap premium while capturing event-driven expansion.
• Avoid chasing BLK/BX as a proxy for the trade: the incremental asset flows to third-party managers may be real, but they are slower and more fee-competitive than the market is likely pricing in.
• If alternatives returns remain below guidance into Q2, fade any post-rally strength in EQH with short-dated put spreads; that is the cleanest way to express disappointment without fighting the merger/buyback support outright.